ClinicalTrials.gg
CompletedNCT06372301DobAttrASUpdated Jun 1, 2026

Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy

An interventional study of Dobutamine stress echocardiography in Transthyretin Amyloid Cardiomyopathy and Aortic Stenosis, sponsored by Steen Hvitfeldt Poulsen. Completed at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Steen Hvitfeldt Poulsen · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Aortic Valve Stenosis with a site in Denmark — 13 open to participants now, 28 under way, none of them phase 3. Aortic Valve Stenosis · Denmark.

Enrollment
38th of 40
15 · median 214
Started
2024
with 6 others
No phase
28 of 73
7 open now
Registered
65th of 73
by date

Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, this one is the 38th largest by enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2024, is one of 28 with no phase, and was the 65th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

13 of the 73 studies in Aortic Valve Stenosis with a site in Denmark are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Aortic Valve Stenosis with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this prospective clinical study is to improve the diagnosis of Low-flow low-gradient aortic stenosis (LF/LG AS), in patients with co-existing wild-type transthyretin cardiac amyloidosis (ATTRwt). The main question it aims to answer is whether the classic dobutamine-stress echocardiography can be used to determine AS severity in patients with ATTRwt and LF/LG AS. We will do that by comparing dobutamine stress echocardiography, with the invasively measured aortic valve area (which is considered as the gold standard).

In addition we aim to assess the degree of myocardial fibrosis and amyloid infiltration, assessed by light microscopy and cardiac magnetic resonance (CMRI) and evaluation of myocyte mitochondrial function by high resolution respirometry and their relation to AS severity and hemodynamic response to dobutamine.

Read the detailed description

Study protocol

A- Baseline assessment: The following will be measured:

  • Blood pressure and heart rate.
  • ECG.
  • Standard echocardiography.
  • Dobutamine stress echocardiography.

B- Catheterization laboratory: The participant will be transferred to the catheterization laboratory after about 1.5-hour recovery period after the end of dobutamine stress echocardiography. The following will be done in the following order:

  • Right heart catheterization and endomyocardial biopsies.
  • Left heart catheterization.
  • Dobutamine challenge: Infusion of increasing dobutamine dosages, with simultaneous invasive measurements.
  • Removal of left and right heart catheters: The catheters will be removed after 5 minutes recovery after dobutamine challenge.

C- Observation: The participant will then be transferred to our out-patient hospital for observation and the participant is expected to be discharged after 2 hours of observation, if no complications arise.

D- CMRI: All the participants will be evaluated with CMRI for estimation of LV mass, T-1 values, and extracellular volume (ECV). This will be scheduled for a separate visit.

Investigations and procedures

  1. Dobutamine Challenges

    Dobutamine challenge will be performed two times at the trial day. The first dobutamine challenge will be performed immediately after the baseline echocardiographic examination. The second dobutamine challenge will be performed no earlier than 2 hours later at the catherization laboratory as described below. Dobutamine, known for its brief half-life of approximately 2 minutes, ensures that its effects diminish rapidly, and the specified two-hour interval guarantees that its influence has subsided.

    Dobutamine infusion will be performed with a stepwise dobutamine dosage increase (dosages: 2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in patients with ongoing beta-blocker treatment to ensure an appropriate dobutamine response.

    The first dobutamine challenge with echocardiography: Blood pressure, heart rate, and standard echocardiography images will be obtained before the infusion start, at each infusion stage, and during the recovery period after the infusion is omitted.

    The second dobutamine challenge with invasive measurements: This will be performed at the catheterization laboratory after the insertion of right and left heart catheters. There must be a minimum of 2 hours between the two dobutamine challenges. Blood pressure, heart rate, and pressure and flow measurements will be obtained before the infusion start, at each infusion stage, and during the recovery period after the infusion is omitted. AVA will be estimated at rest and at each dobutamine dose level using Gorlin formula.

    AVAproj :

    Both echo- and invasive AVAproj will be calculated using the simplified formula (18):

    "AVAproj =AVArest + " " AVApeak- AVArest" /"Qpeak-Qrest" " x (250- Qrest)" For invasive measurements, Q is defined as the directly measured flow rate in ml. per second. For echo-derived AVAproj , Q is defined as the transvalvular flow rate = SV/Ejection time. Here SV is calculated by the LVOTVTI x LVOTarea, and ejection time is measured by CW-Doppler of the valve profile.

    For both the invasive and echo-derived AVAproj, the peak measurements are defined as the measurements that are associated with the highest measured gradients during dobutamine stress.

    As the estimation of AVAproj requires a sufficient increase of the flow of a minimum 15% from baseline; patients who fail to achieve that will be excluded from the primary analysis (18). However, they will be reported in the study results.

  2. Endomyocardial biopsies and biobank Before the right and left heart catheterization are initiated, three endomyocardial biopsies will be taken from the interventricular septum, through the internal jugular vein access (or femoral vein). The first biopsy is for evaluation of mitochondrial function by high resolution respirometry. The other two biopsies are for semi-quantitative evaluation of fibrosis and amyloid infiltration by standard diagnostic light microscopy at the department of pathology at Aarhus University Hospital. Any residual tissue from the first biopsy (to respirometry) will be destroyed after completing the analysis. The biopsies for light microscopy will be prepared, analyzed, and stored in clinical biobank according to the standard clinical practice at the department of pathology.
  3. High Resolution Respirometry Biopsies used for high resolution respirometry are analyzed immediately after being taken. High resolution respirometry is performed at the unit of Clinical Research, Department of Cardiology at Aarhus University Hospital. The procedure is standard in the department.
  4. Cardiac Magnetic Resonance Imaging (CMRI) CMRI scan will be performed to assess LV mass, fibrosis (assessed as late gadolinium enhancement), ECV assessed using T1-mapping, LV volume, left and right ventricular ejection fraction and strain mapping analysis. Gadolinium-based contrast will not be administered to participants with an estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1,73 m2 due to the risk of adverse effects.
03

Conditions studied

  • Transthyretin Amyloid Cardiomyopathy
  • Aortic Stenosis

Keywords

  • ATTR-CM
  • wild-type cardiac amyloidosis
  • aortic stenosis
  • low-flow low-gradient aortic stenosis
  • Dobutamine
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ATTRwt, diagnosis confirmed by 99mtc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid (DPD) scintigraphy, genetic testing, and/or endomyocardial .
  2. Symptomatic patients ( > class I) treated with loop diuretics.
  3. LF/LG AS: Defined as, aortic valve area ≤ 1 cm2 and mean gradient \< 40 mmHg, and SVI ≤35 ml/m2.
  4. Age ≥ 65 years.
  5. Oral and written .

Exclusion criteria

Exclusion Criteria:

  1. Other significant valvular disease.
  2. Known severe coronary artery diseases: left main stem stenosis or 3-vessel disease, or recent acute myocardial infarction (\< 4 weeks).
  3. to the use of dobutamine: Known allergy to dobutamine or sulfite, phaeochromocytoma or ventricular tachycardia (VT).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Co-existing AS and ATTRwt

    Symptomatic patients with co-existing wild-type transthyretin amyloid cardiomyopathy and low-flow low gradient AS.

    Diagnostic Test: Dobutamine stress echocardiography

Interventions

  • Diagnostic testDobutamine stress echocardiography

    Patients will be investigated with dobutamine stress echocardiography (increasing doses of dobutamine infusion and simulatneous echocardiogarphic evaluation) to assess aortic valve area and projected aortic valve area.

06

What researchers measure

Primary outcomes

  1. Primary endpoint is agreement between echocardiography-derived AVAproj and the invasively assessed AVAproj.

    Time frame: Evaluated at the end of dobutamine infusion.

Secondary outcomes

  1. Agreement between echocardiography-derived AVA and invasively assessed AVA at rest and at different dobutamine infusion levels.

    Time frame: Evaluated at rest, at every dobutamine dose-level, and at the end of infusion.

  2. Increase of SVI, LV ejection fraction and LV-global longitudinal strain of 10 % during maximal dobutamine stimulation.

    Time frame: Evaluated at the end of dobutamine infusion.

  3. Agreement between echo- and invasively estimated flow and SVI.

    Time frame: Evaluated at the end of dobutamine infusion.

  4. Degree of myocardial fibrosis, amyloid infiltration and mitochondrial dysfunction and its relation to AS severity and hemodynamic response to dobutamine

    Time frame: CMRI would be performed within a max of 2 months from the trial day.

  5. Change in pulmonary artery wedge pressure and mean pulmonary artery pressure

    Time frame: Evaluated at the end of dobutamine infusion.

  6. Complication rate and symptomatic side effects during dobutamine challenge

    Time frame: Evaluated after couple of days after trial day with dobutamine infusion.

07

Study locations

1 site
  • Department of Cardiology, Aarhus University Hospital
    Aarhus, 8200, Denmark
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Mar 2026, 23 months.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's 23 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Apr 18, 2024
StartActual
Apr 2, 2024
Primary completionActual
Mar 16, 2026
CompletionActual
Mar 16, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06372301
Lead sponsor
Steen Hvitfeldt Poulsen
Responsible party
Steen Hvitfeldt Poulsen (Professor, DMSc., Aarhus University Hospital Skejby) — Sponsor-investigator
First posted
Apr 18, 2024
Start date
Apr 2, 2024
Primary completion
Mar 16, 2026
Completion
Mar 16, 2026
Last update
Jun 1, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion